Zenas BioPharma’s Post

Biotech initial public offerings (IPOs) are essential for funding emerging drugmakers, but recent market fluctuations have made the landscape more challenging. Stay informed with this regularly updated database that tracks IPO activity, company performance, and investment trends in the biotechnology sector from BioPharma Dive: https://lnkd.in/eVzWhfTh

As biotech and biopharma companies face increased pressure to modernize clinical trials, a strategic partnership with an experienced CRO is proving intrinsic to success. Overcome barriers to completion with guidance you can trust. https://bit.ly/4bUYdnQ #biotech #clinicaltrials

After a year of significant volatility, biopharmaceutical leaders are divided on the causes that negatively affected the SPDR S&P Biotech ETF (XBI) and the NASDAQ Biotechnology Index (NBI) valuations. Some point to macroeconomic challenges as the clear drivers, while others cite an oversaturation of public companies or a lack of positive news flow. Uncover more findings and insights in Lazard’s 2024 Global Biopharmaceutical Leaders Study: https://lnkd.in/gjRpuVH7

A critical issue for all emerging biopharmaceutical companies is their valuation- and how clinical trial results from their assets impact on that. This #IQVIA webinar discusses original research by IQVIA statistically analysing the link between valuation changes for biotech companies and types of clinical trials outcomes announcements. Recommended for a statistically robust, quantitative approach to a key #Biotech business issue.

Weekly Watchlist for March 23, 2024. Akebia Therapeutics, Axsom Therapeutics, and TRACON Pharmaceuticals have key catalysts remaining for quarter. Read the full article below to find out more about these catalysts and why we've identified them as important. Subscribe to our newsletter to get this and more sent directly to your inbox. https://lnkd.in/ec-wwWX4 #catalysts #biotechnews #biotechstocks #biotechisback #fasterscience #betherewhenithappens

After a year of significant volatility, biopharmaceutical leaders are divided on the causes that negatively affected the SPDR S&P Biotech ETF (XBI) and the NASDAQ Biotechnology Index (NBI) valuations. Some point to macroeconomic challenges as the clear drivers, while others cite an oversaturation of public companies or a lack of positive news flow. Uncover more findings and insights in Lazard’s 2024 Global Biopharmaceutical Leaders Study: https://lnkd.in/esz5bbfB

Thoughts on this? >> BioAge files for IPO, riding momentum for weight loss drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #pharma #healthcare

After a year of significant volatility, biopharmaceutical leaders are divided on the causes that negatively affected the SPDR S&P Biotech ETF (XBI) and the NASDAQ Biotechnology Index (NBI) valuations. Some point to macroeconomic challenges as the clear drivers, while others cite an oversaturation of public companies or a lack of positive news flow. Uncover more findings and insights in Lazard’s 2024 Global Biopharmaceutical Leaders Study: https://lnkd.in/eDYDqhnY

Thoughts on this? >> BioAge files for IPO, riding momentum for weight loss drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #productmarketing #pharmaceutical #healthcare

Are you a life science company planning an exit into the public markets in 2025? Lets talk! My team and I are ready to help you navigate the process quickly and efficiently. Don't let the next IPO window pass you by! Check out the video link featuring my colleagues and I, and message me directly to set up a meeting today! #IPO #reversemerger #spac #biotech #lifescience #medtech #medicaldevice #pharma #biopharma @transactionadvisory #accountingadvisory #deloitte